Ute Mercker

Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists in Germany, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to—we’re making breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.

Likeminded is a venture-backed mental health care company based in Berlin. Our digital platform provides employees fast, easy, and secure access to various, high-quality mental health care formats like: • Individual Sessions with psychotherapists, coaches, and psychologists • Webinars • Group sessions • On-demand content • and much more We believe that in a world where companies champion mental health, individuals can realize their full potential and live thriving lives. This is why we want to empower more businesses to become mental well-being champions. 🚀 Are you ready to join forces? 👉 Are you looking for more information? Reach out to us: T: +49 30 30809436 M: info@likeminded.care

nilo delivers high-quality mental health support that creates real impact – for both businesses and their employees. What we offer through our easy-to-use digital platform: • 1-on-1 sessions with psychotherapists, coaches, and psychologists • Group sessions for connection and peer support • Webinars & on-demand content for continuous learning • Diverse care formats tailored to individual needs Supporting employee mental health drives significant positive change in short timelines: 96% of our users report “strong improvement”. Additionally, lower stress levels and higher employee resilience pay off for our clients, delivering a 5x return on investment. We are proud to work with companies including Puma, N26, AboutYou, Bosch, Vattenfall, Oatly, A&O Hostels, and many more. *** NEWS *** We have recently joined forces with Likeminded. Together, we aim to transform how companies approach workplace wellbeing and continue to empower businesses to prioritize mental health, enabling employees to reach their full potential. With an expanded range of services, enhanced offerings, and access to psychologists in 50+ languages, we are ready to make an even greater impact. 🚀 Ready to make mental health matter in your organization? 👉🏼 Get in touch anytime: support@nilohealth.com

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

Newsenselab GmbH has developed M-sense Migraine. The application supports migraine sufferers in reducing their headaches and dealing with their condition in a self-determined manner. The innovative digital treatment program was developed together with leading headache specialists.

Selfapy is the first digital self-help solution on prescription against depression and anxiety.

Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen´s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen´s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of lipid metabolism involved in the pathogenesis of fatty liver, diabetes and obesity. Company´s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.

OMEICOS Therapeutics is a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company's novel therapeutic strategy is based upon the discovery of natural CYP-P450 generated metabolites of omega-3 fatty acids, so called epoxyeicosanoids. This new class of bioactive lipid mediators activates type specific cellular endogenous pathways that can be therapeutically deployed in inflammatory, cardiovascular, and other diseases. OMEICOS has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids. These small molecules are orally available and show significantly improved biological activity and pharmacokinetic properties compared to their natural counterparts. The first development project makes use of the strong anti-arrhythmic effect of the compounds for the development of an oral therapy for atrial fibrillation. In contrast to all other anti-arrhythmic drugs that act almost exclusively via direct inhibition of ion channels, OMEICOS'​ substances activate an endogenous cardio-protective signalling pathway that not only stabilizes the heart rhythm, but also provides curative effects to the diseased organ by preventing its electrical and structural remodelling. OMEICOS was founded as a spin-off from the Max-Delbrück-Center in Berlin. Its technology is based on ground breaking scientific results in the field of omega-3 fatty acid metabolism and physiology obtained by the companies’ founders Drs. Wolf-Hagen Schunck, John. R. Falck, Dominik Müller and Robert Fischer.

Based in Berlin, Germany, Humedics GmbH is specialised in rapid and accurate liver function measurement using LiMAx®, an innovative technology for analysing exhaled air. The LiMAx® test provides physicians with a method for quantitatively assessing an individual patient’s liver function capacity within minutes. This enables physicians to select treatment strategies and follow disease progression based on up-to-date knowledge of the functional health of the liver. Current applications, which have already been published in prestigious medical journals, include liver function diagnosis before and after liver transplantation, surgical planning for liver surgery (such as assessing how much liver tissue can be removed without increasing the risk of acute liver failure), and assessment of liver diseases such as fibrosis and cirrhosis. At present, more than 20 studies regarding new indications are being conducted. These include diagnosing and staging of chronic liver diseases such as non-alcoholic steatohepatitis (NASH), as well as selecting, monitoring and managing different oncology treatment options. These studies, initiated by researchers, have already provided evidence of further potential for the LiMAx® tests. The LiMAx® test is in routine clinical use at more than 30 leading university hospitals in Europe. So far, more than 20,000 LiMAx® tests have been performed. The LiMAx® test is commercially available in Germany, Austria and the UK.

Better breast cancer screening should be a universal offering to every woman in the world. Vara’s AI-powered software platform, created with screening radiologists in Germany, mitigates much of the human subjectivity associated with reading mammography results—and reduces the repetitive work screening physicians are routinely subjected to—we’re making breast cancer screening more effective, more measurable, and more accessible for everyone, everywhere. By democratising access to early screening around the world, we deliver measurable impact backed by clinical evidence. We are partnering globally, to deliver breast cancer screening where it is needed most.

Likeminded is a venture-backed mental health care company based in Berlin. Our digital platform provides employees fast, easy, and secure access to various, high-quality mental health care formats like: • Individual Sessions with psychotherapists, coaches, and psychologists • Webinars • Group sessions • On-demand content • and much more We believe that in a world where companies champion mental health, individuals can realize their full potential and live thriving lives. This is why we want to empower more businesses to become mental well-being champions. 🚀 Are you ready to join forces? 👉 Are you looking for more information? Reach out to us: T: +49 30 30809436 M: info@likeminded.care

nilo delivers high-quality mental health support that creates real impact – for both businesses and their employees. What we offer through our easy-to-use digital platform: • 1-on-1 sessions with psychotherapists, coaches, and psychologists • Group sessions for connection and peer support • Webinars & on-demand content for continuous learning • Diverse care formats tailored to individual needs Supporting employee mental health drives significant positive change in short timelines: 96% of our users report “strong improvement”. Additionally, lower stress levels and higher employee resilience pay off for our clients, delivering a 5x return on investment. We are proud to work with companies including Puma, N26, AboutYou, Bosch, Vattenfall, Oatly, A&O Hostels, and many more. *** NEWS *** We have recently joined forces with Likeminded. Together, we aim to transform how companies approach workplace wellbeing and continue to empower businesses to prioritize mental health, enabling employees to reach their full potential. With an expanded range of services, enhanced offerings, and access to psychologists in 50+ languages, we are ready to make an even greater impact. 🚀 Ready to make mental health matter in your organization? 👉🏼 Get in touch anytime: support@nilohealth.com

Aignostics combines proprietary access to multimodal clinical datasets, industry-leading AI technologies, and rigorous science to develop best-in-class insights for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development across multiple therapeutic areas. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading VC investors and has operations in Berlin and New York.

The EU Malaria Fund is a public-private partnership between the European Union, International Organizations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally. It has been initiated by kENUP Foundation, The Fund was inaugurated during a public ceremony held online on June 3, 2020.